An isolated antibody that specifically binds to human oncostatin M, which blocks the interaction between human oncostatin M and gp130 and which comprises: (i) a light chain variable region amino acid sequence of SEQ ID NO:51 and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (ii) a light chain variable region amino acid sequence of SEQ ID NO:49 and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (iii) a light chain variable region amino acid sequence of SEQ ID NO:50 and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (iv) a light chain variable region amino acid sequence of SEQ ID NO:52 and a heavy chain variable region amino acid sequence of SEQ ID NO:54; (v) a light chain variable region amino acid sequence of SEQ ID NO:53 and a heavy chain variable region amino acid sequence of SEQ ID NO:54; (vi) a light chain variable region amino acid sequence of SEQ ID NO:49 and a heavy chain variable region amino acid sequence of SEQ ID NO:54; (vii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 30, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (viii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 31, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (ix) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 33, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (x) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 34, 42 and 45 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xi) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 35, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 36, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xiii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 41, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xiv) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 35, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:54; or (xv) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 40, 26 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:54. (i) a light chain variable region amino acid sequence of SEQ ID NO:51 and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (ii) a light chain variable region amino acid sequence of SEQ ID NO:49 and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (iii) a light chain variable region amino acid sequence of SEQ ID NO:50 and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (iv) a light chain variable region amino acid sequence of SEQ ID NO:52 and a heavy chain variable region amino acid sequence of SEQ ID NO:54; (v) a light chain variable region amino acid sequence of SEQ ID NO:53 and a heavy chain variable region amino acid sequence of SEQ ID NO:54; (vi) a light chain variable region amino acid sequence of SEQ ID NO:49 and a heavy chain variable region amino acid sequence of SEQ ID NO:54; (vii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 30, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (viii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 31, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (ix) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 33, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (x) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 34, 42 and 45 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xi) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 35, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 36, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xiii) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 41, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:55; (xiv) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 35, 42 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:54; or (xv) a light chain variable region comprising CDRs 1, 2 and 3 of SEQ ID NOs: 40, 26 and 27 in an IGKV4-1 framework and a heavy chain variable region amino acid sequence of SEQ ID NO:54.